Trial Profile
A phase I trial multiple dose-escalation study assessing tolerability, pharmacokinetics and pharmacodynamics of CMAB007 in healthy Chinese subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 02 Dec 2015 New trial record